Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-354031
- Background Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively. Case presentation We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensiveBackground Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively. Case presentation We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab. Conclusion Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.…
Autor(en): | Dominik Lehrieder, Nikolaos Zapantis, Mirko Pham, Michael Klaus Schuhmann, Axel Haarmann |
---|---|
URN: | urn:nbn:de:bvb:20-opus-354031 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Neurologische Klinik und Poliklinik |
Medizinische Fakultät / Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Frontiers in Neurology |
Erscheinungsjahr: | 2023 |
Band / Jahrgang: | 14 |
Aufsatznummer: | 1297341 |
Originalveröffentlichung / Quelle: | Frontiers in Neurology (2023) 14:1297341. https://doi.org/10.3389/fneur.2023.1297341 |
DOI: | https://doi.org/10.3389/fneur.2023.1297341 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | AQP4; CD19; NMOSD; case report; inebilizumab; longitudinally extensive transverse myelitis; optic neuritis; seronegative |
Datum der Freischaltung: | 31.05.2024 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |